Geographic differences in mortality of young children with sickle cell disease in the United States.
OBJECTIVE
Because geographic differences in health care have been found for many diseases, including those affecting children, there are probably geographic differences in the health care of young children with sickle cell disease. Consequently, survival of young children with sickle cell disease might differ among geographic areas. This study's objective was to identify areas in the United States where young children with sickle cell disease are at especially high and low risk of dying.


METHODS
Using U.S. death certificate data from 1968 through 1992, the authors calculated the mortality rates of 1- through 4-year-old black children with sickle cell disease for states, counties, and cities. Deaths from trauma, congenital anomalies, and perinatal conditions were excluded.


RESULTS
From 1968 through 1980 and from 1981 through 1992, 1- through 4-year-old black children with sickle cell disease in Florida had a markedly higher risk of dying, and those in Pennsylvania had a markedly lower risk of dying, than the average 1- through 4-year-old black child with the disease in the United States. From 1981 through 1992, 1- through 4-year-old black children with sickle cell disease in Maryland had the lowest mortality rate in the nation. During the same time period, 1- through 4-year-old black children with sickle cell disease in five counties in Florida were at especially high risk, while in Baltimore no young black children with the disease died. These geographic differences in mortality of black children with sickle cell disease greatly exceeded geographic differences in mortality of black children without the disease.


CONCLUSIONS
Marked differences exist across the United States in mortality of young black children with sickle cell disease. To improve survival for children with the disease in high mortality areas, evaluations should be made of the accessibility and quality of medical care, and of parents' health care seeking behavior and compliance with antibiotic prophylaxis. In addition, efforts should be made to understand and duplicate the success of treatment programs in low mortality areas.
Davis
H
H
Office of Epidemiology and Biostatistics, Food and Drug Administration, Rockville MD 20857, USA. davisha@cder.fda.gov
Gergen
P J
PJ
Moore
R M
RM
D000755:Anemia, Sickle Cell / Q000401:mortality*; D044383:Black People; D002675:Child, Preschool; D003644:Death Certificates; D006801:Humans; D007223:Infant; D007226:Infant Mortality / Q000639:trends; D007231:Infant, Newborn; D009309:National Center for Health Statistics, U.S.; D010342:Patient Acceptance of Health Care; D011159:Population Surveillance; D011787:Quality of Health Care; D012111:Residence Characteristics; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D001741:Black or African American